Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

thehindubusinessline.com - Spotlighting the gender gap in pharma research
Spotlighting the gender gap in pharma research
BusinessLine

The European Medicines Agency (EMA) is launching initiatives to better embed women's health considerations in medicines development and regulation. Women live longer than men on average but spend more of their lives in poorer health. This disparity…

thehindubusinessline.com - Team BL - Stock Market Today Live, July 13: Stock to buy today: Piramal Pharma
Stock Market Today Live, July 13: Stock to buy today: Piramal Pharma
BusinessLine

Sensex Today, Nifty 50 | Stock Market Live Updates - Find here all the live updates related to Sensex, Nifty, BSE, NSE, share prices and Indian stock markets for 13th July 2026. Published on July 13, 2026 01:08…

marketbeat.com - Zealand Pharma A/S (OTCMKTS:ZLDPF) Given Consensus Recommendation of 'Hold' by Analysts
Zealand Pharma A/S (OTCMKTS:ZLDPF) Given Consensus Recommendation of 'Hold' by Analysts
MarketBeat

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) have been given a consensus rating of 'Hold' by the nine analysts that are covering the firm, MarketBeat.com reports. Seven equities research analysts have rated the stock with a hold…

dev.to - Scott Shoemaker - Architecting MedReach AI: Solving Data Rot and Regulatory Bottlenecks in Pharma Marketing
Architecting MedReach AI: Solving Data Rot and Regulatory Bottlenecks in Pharma Marketing
DEV Community

As we kick off Month 1 of our AI Software Development Capstone, I am thrilled to officially introduce the project I will be co-developing over the next five months: MedReach AI. In my role as the Project/Scrum Master and Backend Architect, I am…

bloomberg.com - Watch The $360 Billion Market that Medicine Got Wrong for 20 Years
Watch The $360 Billion Market that Medicine Got Wrong for 20 Years
Bloomberg

The $360 billion dollar women's health market is made of several categories that are often overlooked – one of which is menopause. The condition has gone largely unnoticed by pharma and biotech firms, employers, and investors, despite…

cnbc.com - Zev Fima - Here are the 3 big things we're watching in the stock market this week
Here are the 3 big things we're watching in the stock market this week
CNBC

The common thread linking this week's biggest market events is the state of the U.S. economy. The biggest day is Tuesday, when the nation's largest banks — JPMorgan, Bank of America and Citigroup, along with Club names Wells Fargo and…

seekingalpha.com - Terry Chrisomalis - BridgeBio: 'Strong Buy' Attruby Differentiation And Several NDA Submissions In Play (NASDAQ:BBIO)
BridgeBio: 'Strong Buy' Attruby Differentiation And Several NDA Submissions In Play (NASDAQ:BBIO)
Seeking Alpha

BridgeBio Pharma (BBIO) remains a 'Strong Buy,' driven by regulatory approvals, robust pipeline progress, and significant commercial momentum for Attruby in ATTR-CM. Company has achieved U.S. and international approvals for acoramidis, with Q1 2026…

fool.com - Jonathan Ponciano - UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run
UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run
The Motley Fool

Mark Schoenberg, Chief Medical Officer, sold 10,000 ordinary shares of UroGen Pharma Ltd. (URGN 4.15%) on July 9, 2026, for a total value of $400,000, according to an SEC Form 4 filing. MetricValueTransaction value$400,000Shares…

afr.com - Sarah Thompson, Kanika Sood, Emma Rapaport - Shareholders eye break-up as shares languish
Shareholders eye break-up as shares languish
Australian Financial Review

The battle for Mayne Pharma was a headline grabber in 2025: a dramatic Treasurer intervention, a high-stakes manoeuvre at the Takeovers Panel and much hand-wringing over the application of material adverse change clauses. But since the collapse of…

rediff.com - SHOBHA WARRIER - 25 Year Old's Big Dream: Manufacturing In Space
25 Year Old's Big Dream: Manufacturing In Space
Rediff.com

'ISRO is planning to build a Bharatiya Antariksh Station by 2030. So, our goal is to create a vehicle that can supply modules to the Bharatiya Antariksh Station and bring the products back.' There is not a child who has not dreamt of becoming an…

seekingalpha.com - Albert Anthony - Ventas: Ahead Of Q2 Results, Lots To Like About This Senior-Care REIT (NYSE:VTR)
Ventas: Ahead Of Q2 Results, Lots To Like About This Senior-Care REIT (NYSE:VTR)
Seeking Alpha

Albert Anthony is the pen name of a business author on Amazon and his newest book is 'How To Pick Stocks: 8 Steps For Long-Term Investing with Fundamental & Technical Analysis,' now available as a 2026 edition paperback and Kindle ebook in several…

indianexpress.com - Education Desk - Indian Army Agniveer Result 2026 out at joinindianarmy.nic.in; check merit list, next steps
Indian Army Agniveer Result 2026 out at joinindianarmy.nic.in; check merit list, next steps
The Indian Express

3 min read New Delhi Make us preferred source on Google Indian Army Agniveer CEE 2026 Results Out: The Indian Army has declared the Agniveer Common Entrance Examination (CEE) Result 2026. Candidates who appeared for the online written examination…

fool.com - Adria Cimino - Billionaire Ken Griffin Boosted His Stake in This Dividend King by 146%. Here's Why It's a Dream Stock for Risk-Averse Investors.
Billionaire Ken Griffin Boosted His Stake in This Dividend King by 146%. Here's Why It's a Dream Stock for Risk-Averse Investors.
The Motley Fool

Investors pay careful attention to Ken Griffin's moves for one major reason: The founder of Citadel has an extremely solid track record of success. Citadel, which oversees $69 billion, in January was named the most profitable hedge fund ever…

theguardian.com - Kat Lay - First patients enrolled in record-breaking Ebola treatment trial in DRC
First patients enrolled in record-breaking Ebola treatment trial in DRC
The Guardian

There is no approved drug to help the medical teams scrabbling to save lives in the Ebola outbreak in the Democratic Republic of the Congo – but there are hopes that could change within months as the first patients are enrolled in a…

marketbeat.com - Teva Pharmaceutical Industries (NYSE:TEVA) Cut to 'Hold' at Wall Street Zen
Teva Pharmaceutical Industries (NYSE:TEVA) Cut to 'Hold' at Wall Street Zen
MarketBeat

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a 'buy' rating to a 'hold' rating in a research report issued to clients and investors on Sunday. MarketBeat Week in…

Receive a Daily briefing on Pharma Industry News

Get Started